This 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.
The KDIGO heatmap is a useful tool for staging CKD, assessing risk of CKD progression, and initiating conversations on potential interventions.
ADA, KDIGO, and AACE recommend both eGFR and albuminuria screening at least annually in all patients with T2D.
The preferred test for albuminuria is UACR.
CKD testing in patients with diabetes is underutilized, particularly UACR testing.
This episode 2 of a 6-part podcast mini-series, organized and supported by Bayer, is intended for healthcare professionals practicing in the US. Our aim is to raise awareness of the importance of early diagnosis and appropriate management of chronic kidney disease (CKD) in patients with type 2 diabetes in order to slow progression of CKD and reduce the risk of premature cardiovascular morbidity and mortality.
Drs. Susanne B. Nicholas (Nephrologist and Professor of Medicine and Clinical Hypertension Specialist in the Division of Nephrology at UCLA) and Radica Alicic (Internist and Clinical Professor at the University of Washington) highlight the KDIGO heatmap as a key tool for CKD staging and assessing progression risk and guidelines that recommend annual eGFR and albuminuria screening, as CKD testing remains underutilized in T2D patients.
